MATERIAL AND METHODS
We studied the number of patients treated with the biological reference products (BRP) and with their corresponding biosimilar, since the introduction of etanercept (April 2018) and adalimumab BS (January 2019) in the hospital until September 2019.

RESULTS

**ETANERCEPT**: 211 patients treated with etanercept

**DISEASES DISTRIBUTION**
- Spondyloarthropathy: 13.4%
- Rheumatoid arthritis: 14.8%
- Psoriatic arthritis: 36.7%
- Psoriasis: 35.1%

**PERCENTAGES OF PATIENTS WITH ETANERCEPT BRP/BS**
- ETANERCEPT BRP: 58.3%
- ETANERCEPT BS: 41.7%

**NEW TREATMENTS**: 38.4%

**SWITCHES**: 3.3%

**ADALIMUMAB**: 452 patients treated with adalimumab

**DISEASES DISTRIBUTION**
- Arthopathies: 6.4%
- Inflammatory Bowel Disease: 16.4%
- Psoriasis: 46.2%
- Others: 31.0%

**PERCENTAGES OF PATIENTS WITH ADALIMUMAB BRP/BIOSIMILAR**
- ADALIMUMAB BRP: 81.1%
- ADALIMUMAB BS: 18.9%

**NEW TREATMENTS**: 17.0%

**SWITCHES**: 1.9%

CONCLUSION
- The use of biosimilar etanercept and adalimumab is highly accepted when initiating a new treatment and switching is starting to grow, especially in psoriasis.
- It is important to design a strategy that could enhance the switching from the BRP to the BS drug in other pathologies than psoriasis, where patients are chronic and will remain in treatment for a long period of time.